Longitudinal study of influenza molecular viral shedding in Hutterite communities.

BACKGROUND The nature of influenza viral shedding during naturally acquired infection is not well understood. METHODS A cohort study was conducted in Hutterite colonies in Alberta, Canada. Flocked nasal swabs were collected during 3 influenza seasons (2007-2008 to 2009-2010) from both symptomatic and asymptomatic individuals infected with influenza. Samples were tested by real-time reverse-transcription polymerase chain reaction for influenza A and influenza B, and the viral load (VL) was determined for influenza A positive samples. RESULTS Eight hundred thirty-nine participants were included in the cohort; 25% (208) tested positive for influenza viruses. They experienced 238 episodes of viral shedding, of which 23 (10%) were not accompanied by symptoms. For seasonal and pandemic H1N1, VL peaked at or before onset of acute respiratory infection. For H3N2, VL peaked 2 days after the onset of acute respiratory infection, which corresponded to peaks in systemic and respiratory symptom scores. Although the duration of shedding was shorter for asymptomatic participants, the peak level of VL shedding was similar to that of symptomatic participants. Viral loads for children and adults revealed similar patterns. CONCLUSIONS Molecular viral shedding values follow symptom scores, but timing of peak VL varies by subtype. Asymptomatic infections are infrequent.

[1]  L. Nashef,et al.  Acute phase response of serum amyloid A protein and C reactive protein to the common cold and influenza. , 1985, Journal of clinical pathology.

[2]  R. Karron,et al.  Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers , 1992, Journal of clinical microbiology.

[3]  C. Hall,et al.  Children with influenza A infection: treatment with rimantadine. , 1987, Pediatrics.

[4]  L. Finelli,et al.  Emergence of a novel swine-origin influenza A (H1N1) virus in humans. , 2009, The New England journal of medicine.

[5]  B. Murphy,et al.  ADVANTAGE OF LIVE ATTENUATED COLD-ADAPTED INFLUENZA A VIRUS OVER INACTIVATED VACCINE FOR A/WASHINGTON/80 (H3N2) WILD-TYPE VIRUS INFECTION , 1984, The Lancet.

[6]  T. Mazzulli,et al.  Self-Collected Mid-Turbinate Swabs for the Detection of Respiratory Viruses in Adults with Acute Respiratory Illnesses , 2011, PloS one.

[7]  Simon Cauchemez,et al.  Transmission Characteristics of the 2009 H1N1 Influenza Pandemic: Comparison of 8 Southern Hemisphere Countries , 2011, PLoS pathogens.

[8]  R. Douglas,et al.  Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. , 1971, The Journal of infectious diseases.

[9]  R. Betts,et al.  Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. , 1998, Vaccine.

[10]  Benjamin J Cowling,et al.  Viral Shedding and Clinical Illness in Naturally Acquired Influenza Virus Infections , 2010, The Journal of infectious diseases.

[11]  F. Hayden,et al.  Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans , 1994, Antimicrobial Agents and Chemotherapy.

[12]  F. Hayden,et al.  Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. , 1997, The Journal of infectious diseases.

[13]  F. Hayden,et al.  Respiratory nitric oxide levels in experimental human influenza. , 1998, Chest.

[14]  G. Schiff,et al.  Complement is activated in the upper respiratory tract during influenza virus infection. , 1991, The American review of respiratory disease.

[15]  B. Murphy,et al.  Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. , 1990, The Journal of infectious diseases.

[16]  A. Leibovitz,et al.  Correlated studies of a recombinant influenza-virus vaccine. IV. Protection against naturally occurring influenza in military trainees. , 1971, The Journal of infectious diseases.

[17]  S. Carruthers,et al.  Development and Evaluation of a Flocked Nasal Midturbinate Swab for Self-Collection in Respiratory Virus Infection Diagnostic Testing , 2010, Journal of Clinical Microbiology.

[18]  M. Epstein,et al.  DEATHS IN THE COMMUNITY. , 1964, Lancet.

[19]  F. Hayden,et al.  Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. , 1998, The Journal of clinical investigation.

[20]  J. W. Little,et al.  Attenuated influenza produced by experimental intranasal inoculation , 1979, Journal of medical virology.

[21]  B. Murphy,et al.  Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. , 1988, The Journal of infectious diseases.

[22]  P. Daley,et al.  Comparison of Flocked and Rayon Swabs for Collection of Respiratory Epithelial Cells from Uninfected Volunteers and Symptomatic Patients , 2006, Journal of Clinical Microbiology.

[23]  F. Hayden,et al.  Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. , 1996, JAMA.

[24]  F. Hayden,et al.  Increased Interleukin-6 Levels in Nasal Lavage Samples following Experimental Influenza A Virus Infection , 1998, Clinical Diagnostic Laboratory Immunology.

[25]  A. Frank,et al.  Patterns of shedding of myxoviruses and paramyxoviruses in children. , 1981, The Journal of infectious diseases.

[26]  N. Ferguson,et al.  Time lines of infection and disease in human influenza: a review of volunteer challenge studies. , 2008, American journal of epidemiology.

[27]  J. Langley,et al.  Prevention of influenza in the general population , 2004, Canadian Medical Association Journal.

[28]  W. Doyle,et al.  Illness and Otological Changes During Upper Respiratory Virus Infection , 1999, The Laryngoscope.

[29]  F. Hayden,et al.  Nasal and Otologic Effects of Experimental Influenza a Virus Infection , 1994, The Annals of otology, rhinology, and laryngology.

[30]  P. Wright,et al.  Differing virulence of H1N1 and H3N2 influenza strains. , 1980, American journal of epidemiology.

[31]  F. Hayden,et al.  Influenza A virus--induced acute otitis media. , 1995, The Journal of infectious diseases.

[32]  W. M. Shepherd,et al.  Intranasal lymphoblastoid interferon ("Wellferon") prophylaxis against rhinovirus and influenza virus in volunteers. , 1984, Journal of interferon research.

[33]  R. Betts,et al.  Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans , 1994, Journal of clinical microbiology.

[34]  Pan Xin,et al.  Novel Swine-Origin Influenza A(H1N1) Virus , 2009 .

[35]  Keiji Fukuda,et al.  Influenza-associated hospitalizations in the United States. , 2004, JAMA.

[36]  B. Murphy,et al.  Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine , 1986, Journal of clinical microbiology.

[37]  R. Couch,et al.  Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. , 1991, American journal of epidemiology.